Management

James R. McCullough

Chief Executive Officer

Mr. McCullough is one of our founders and has been Chief Executive Officer since inception in May of 2008. From March of 2001 to October of 2006, Mr. McCullough was the Chief Executive Officer of AusAm Biotechnologies, Inc. a biotechnology company developing diagnostics to identify kidney and cardiovascular diseases. At AusAm, Mr. McCullough oversaw commercial development, FDA clearance, and marketing and distribution for Accumin, a diagnostic for detection of patients at risk for early-stage kidney and cardiovascular disease. He received his B.A. from Boston University in 1990, and his M.B.A. from the Columbia Graduate School of Business in 1995.

Wayne D. Comper Ph.D., D.Sc.

Chief Science Officer

Dr. Comper is one of our founders and has been a Director and Chief Science Officer since inception. From March of 2001 to October of 2006, Dr. Comper was Chief Science Officer of AusAm Biotechnologies, Inc., a biotechnology company developing diagnostics to identify kidney and cardiovascular diseases. From 1991 until 2004, Dr. Comper was Reader of Biochemistry and Molecular Biology at Monash University, Clayton, Victoria, Australia. From 1974 to 1976, Dr. Comper was a postdoctoral fellow at Northwestern University Medical School in Chicago. From 1976 to 1978, he was a visiting scientist in the Department of Medical and Physiological Chemistry, Uppsala University, Sweden. In 1988, he was a Visiting Professor, Nephrology Section, Rush Medical School, Chicago, Illinois.

Directors

Georg Nebgen, Ph.D.

Chairman

Dr. Georg Nebgen is a co-founder and Managing General Partner of NGN Capital. He joined from MPM Capital where he had previously been a Principal at MPM Capital in Boston and Managing Director of MPM Capital GmbH. Prior to this, Dr. Nebgen was with Schering-Plough Corporation, as Managed Care Area Manager for New England. Prior to this, Dr. Nebgen had served in Schering-Plough's subsidiary in Switzerland as Business Unit Head, Oncology & Biotech and Business Unit Head, Cardiovascular & CNS. He obtained his doctorate in Pharmaceutical Technology Sciences from the University of Bonn, Germany and his executive MBA from the University of St. Gallen, Switzerland. He served as the President of the German-American Business Council in Boston. Dr. Nebgen currently serves on the Board of Directors of Javelin Pharmaceuticals, Inc. (AMEX: JAV), Artisan Pharma, Inc., KIKA Medical, Inc., and Tigris Pharmaceuticals, Inc. He also serves as a Director for ACT Biotech, Valtech Cardio and Vivaldi Biosciences.

James R. McCullough

Chief Executive Officer

Mr. McCullough is one of our founders and has been Chief Executive Officer since inception in May of 2008. From March of 2001 to October of 2006, Mr. McCullough was the Chief Executive Officer of AusAm Biotechnologies, Inc. a biotechnology company developing diagnostics to identify kidney and cardiovascular diseases. At AusAm, Mr. McCullough oversaw commercial development, FDA clearance, and marketing and distribution for Accumin, a diagnostic for detection of patients at risk for early-stage kidney and cardiovascular disease. He received his B.A. from Boston University in 1990, and his M.B.A. from the Columbia Graduate School of Business in 1995.

Geert-Jan Mulder, M.D.

Director

Geert-Jan Mulder, General Partner at Forbion Capital Partners (formerly ABN AMRO Capital Life Sciences.), is an M.D. and accredited Pharmaceutical Physician. Before joining the pharmaceutical industry, he gained his clinical experience at the University Medical Center of Utrecht (UMC) in the field of Obstetrics and Gynecology. He then joined Searle (now Pfizer) as Medical Advisor in the field of arthritis and pain (COX-2 technology) and worked on the local and European positioning of celecoxib. After working at Searle, he joined Byk Gulden (now Nycomed) where his department was responsible for clinical development in The Netherlands dealing with the design and execution of numerous corporate clinical trials in the fields of Gastroenterology, Respiratory (asthma and COPD), Intensive Care Medicine and Imaging. Dr. Mulder currently serves on a number of boards and assists portfolio companies in their clinical development programs and overall strategy.

Peter Johann, Ph.D.

Director

Dr. Johann is a Managing General Partner of NGN Capital. He joined NGN Capital from Boehringer Ingelheim, where he was the Division Head of Corporate Development responsible for strategic planning, strategic projects, M&A, business development and licensing. Prior to this, Mr. Johann has served at F. Hoffmann-La Roche as Global Business Leader where he led global business teams and was responsible for global marketing of oncology products as well as evaluation of pipeline products from internal and external sources. Dr. Johann joined Roche from Boehringer Mannheim, where he was Head of Business Development and Marketing Molecular Medicine. Dr. Johann obtained his Ph.D. from the Technical University Munich. Dr. Johann holds Board seats with Cerapedics (Observer), Exosome, Horizon Pharma (after the Nitec merger), Micromet, NaniRx, Resverlogix, Vivaldi Biosciences and held Board and Observer seats at Jerini and Santhera respectively.

Joseph Boystak

Director

Mr. Boystak joined our Board of Directors in May of 2008. Mr. Boystak serves as the CEO of Hudson/Brightwaters, a life-sciences merchant banking firm with offices in New York and Los Angeles. He is also the CEO of Brightwaters Capital, LLC, a private equity group focused in the health care and life sciences sectors. Mr. Boystak has 25 years of investment banking and principal investing experience and has been directly involved in over $15 billion of transactions in the health care industry. He served as Founding Managing Director of Global Life Sciences Group with Jefferies & Co. Prior to that he served as Managing Director & Head of Health Care Banking at Tucker Antony Sutro and Security Pacific Merchant Bank. He also served as a Vice President of Investment Banking at Dean Witter Reynolds. Mr. Boystak currently serves on Cardioceutics, NanoPacific Holdings, VigilNet America, WaterStyle Holdings and OncoTx boards.